05/05/2021 - General information
The General Assembly of the ISCIII Clinical Research Support Platform has elected Dr. Ana Aldea, Head of the Clinical Pharmacology Section at Hospital del Mar and coordinator of the IMIM Clinical Research Unit, as a member of the Steering Committee. The ISCIII Clinical Research Support Platform, (SCReN, Spanish Clinical Research Network), is a network structure supporting clinical research and is made up of the 34 units financed in the PT20 call of the Carlos III Health Institute, distributed among hospitals throughout the National Health System (SNS). This network structure, acting in a coordinated manner, will be responsible for executing the actions necessary to achieve the Platform's objectives.
29/04/2021 - General information
The benchmark meeting in the field of immunotherapy cancer treatment was held once again, on April 9, in a hybrid format. This year, the presentations focused on the research and development of this type of treatment for various types of tumours, as well as molecular diagnostics. Understanding which factors make immunotherapy work in some cancer patients and not in others, the structure and genetics of tumours to help select the most appropriate treatment, is the current focus of research in this field. This was evident at the new edition of the Optimizing Immunotherapy, New Approaches, Biomarkers, Sequences and Combinations congress, held on 9 April in a hybrid format and organised by the Hospital del Mar Medical Research Institute (IMIM) and Hospital del Mar. The meeting brought together around twenty of the world's leading experts in research and clinical application of immunotherapy treatments to analyse the latest breakthroughs and the future of immunotherapy. It was backed by the SEOM, SOGUC and CIBERONC.
Més informació "The future of immunotherapy at the Optimizing Immunotherapy Congress"
28/04/2021 - General information
The head of the Epilepsy Unit at Hospital del Mar and coordinator of the Epilepsy Research Group at the Hospital del Mar Medical Research Institute has been appointed Spanish Society of Neurology representative in the field of epilepsy to the top European scientific body in the field of neurology.
23/04/2021 - General information
In less than 12 months, the collaboration between Chemotargets and Galyan Bio yields a scaffold for first-in-class clinical candidates in difficult area of neurodegenerative disease. Chemotargets employed its proprietary AI-driven de novo drug design methods in collaboration with Gaylan Bio to rapidly design novel molecules which would bind to the previously 'undruggable' Huntington's Disease target. Huntington's Disease (HD) is a neurodegenerative disorder that affects thousands of patients worldwide. There is currently no cure or disease modifying treatment for HD. This is why US-based company Galyan Bio and Barcelona-based Chemotargets joined efforts to design a first in class drug for HD. The result has been the generation of a first-in-class drug candidate for HD. Galyan Bio plans to start clinical trials in HD in 2022. Galyan Bio's new treatment is intended to slow down the disease in symptomatic patients and delay manifestation of HD in symptom-free gene carriers.
22/04/2021 - General information
Dr. Anna Bigas, coordinator of the Stem cells and cancer Research Group of the Hospital del Mar Medical Research Institute (IMIM) and scientific director of the CIBER Oncology has been chosen one of the Top 100 Women Leaders in Spain. This is a ranking created by Mujeres & Cia in 2011, an online magazine of reference among professional women that aims to make female talent visible and build a society based on equality. On the afternoon of April 21, the Top 100 Gala was held, this year in hybrid format, which was attended by Nadia Calviño, Second Vice President of the Government, soprano Pilar Navarro and TV presenter Sonsoles Onega. At the event, the chosen ones were announced, including Dr. Anna Bigas in the category of Academics, researchers and thinkers. Of the 100 chosen, 50 are chosen by a jury, 40 by Mujeres & Cia and 10 by the public through voting.
Més informació "Anna Bigas, one of the Top 100 Women Leaders in Spain"
13/04/2021 - General information
The head of the Digestive Oncology section in the Medical Oncology Service at Hospital del Mar is taking on this new role in the ESMO Faculty until 2025. From now on, she will be part of the group of experts who collaborate with the organisation to fulfil its educational responsibilities. Dr. Clara Montagut is now a member of the ESMO Faculty, the teaching body of the European Society of Medical Oncology, specifically in the gastrointestinal, colon and rectal tumours group. The head of Digestive Oncology at Hospital del Mar and the clinical and translational research group laboratory for new therapies and biomarkers in colon and rectal cancer at the Hospital del Mar Medical Research Institute (IMIM), will form part of the group of experts from the organisation who offer advice and support to help the society fulfil its educational responsibilities.
12/03/2021 - General information
The head of Addictions Process at the Hospital del Mar Institute of Neuropsychiatry and Addictions (INAD) and coordinator of the Addictions research group at the Hospital del Mar Medical Research Institute has been recognised for her contribution to addictions research in Europe. Dr. Marta Torrens has be honoured with the EUFAS EAR 2020 Award, presented by theEuropean Federation of Addiction Societies and the journal European Addiction Research. This award recognises the work of the head of the INAD Addiction Process in terms of European research into addictions. The award has been presented since 2016 to figures who are outstanding in the field of addiction research. The awarding committee considered that the work of Dr. Torrens, with more than 200 high quality articles published in international journals, has made a substantial contribution to the advancement of translational research in this field, and has been instrumental in the introduction of various tools and scales for diagnosing and assessing dual pathology
21/03/2021 - General information
March 21st is World Down Syndrome Day and we are joining in by launching the "21 reasons to collaborate with science" campaign. The goal is to promote clinical research into people with Down's syndrome, to encourage them to get involved in the clinical studies that are currently being carried out and, in this way, to help improve the health and quality of life of these people. Through the 21 reasons campaign, the team of Dr. Rafael de la Torre, director of the Neurosciences research programme at the Hospital del Mar Medical Research Institute, wants to raise awareness and encourage people with Down syndrome to get involved in the studies they are conducting. According to Dr. de la Torre, "The therapeutic approach to these people, given their genetic features, has been quite specific, and the more knowledge we have, the more we will be able to adjust the therapy to their needs. Certain medical practices should also be studied in individuals with this syndrome."
21/03/2021 - General information
Down syndrome (DS) is the most common chromosomal abnormality in children leading to lifelong intellectual disability. Over one million people in the EU and US have DS, and its prevalence has increased in the last ten years. Thanks to significant advances in medical and social care, the life expectancy of individuals with DS has increased greatly, so that many of them reach even the age of 60-70. DS causes lifelong cognitive dysfunction, which results in important negative consequences for these individuals, their families and society. Despite the heavier social burden and the greater medical needs linked to this intellectual disability, there isn't an approved therapy for DS-related cognitive dysfunction yet. Furthermore, though there are specific cognitive screening tests designed for individuals with DS, no official guidelines have been developed to assess their cognitive deficits or their impact on quality of life of DS individuals and their families.
16/02/2021 - General information
Researchers of the Research Programme on Biomedical Informatics (GRIB) from UPF and Hospital del Mar Medical Research Institute (IMIM) have identified behavioural and linguistic changes in tweets in Spanish published by users suffering from depression and who are taking medication to treat this disease. Their work has been published in Journal of Medical Internet Research and was led by Ferran Sanz; with Angela Leis and Francesco Ronzano as first authors, who conducted the work together with Miguel Angel Mayer and Laura I Furlong, all from the Integrative Biomedical Informatics research group. Depression is one of the most widespread mental illnesses. According to the World Health Organization, it affects more than 322 million people of all ages and is one of the leading causes of disability worldwide.
Servei de Comunicació:
Marta Calsina(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
